Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina



Status:Completed
Conditions:Angina, Peripheral Vascular Disease, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:21 - 80
Updated:12/20/2018
Start Date:April 2012
End Date:November 2015

Use our guide to learn which trials are right for you!

A Prospective, Randomized, Double-blinded, Active-control and Unblinded Standard of Care (SOC) Controlled Study to Determine the Efficacy and Safety of Targeted Intramyocardial Delivery of Autologous CD34+ Cells (Auto-CD34+ Cells) for Increasing Exercise Capacity During Standardized Exercise Testing in Subjects With Refractory Angina Pectoris and Chronic Myocardial Ischemia

The purpose of the study is to assess the safety and efficacy of targeted intramyocardial
delivery of Auto-CD34+ cells for increasing exercise time and amelioration of anginal
symptoms in subjects with refractory angina and chronic myocardial ischemia.


Main Inclusion Criteria:

- Male or female participants who are 21 to 80 years of age at the time of signing the
informed consent.

- Participants with Canadian Cardiovascular Society (CCS) class III or IV chronic
refractory angina.

- Participants without control of their angina symptoms in spite of maximal tolerated
doses of anti-angina drugs. Participants must be on optimal therapy for their angina
and must have been on a stable anti-anginal medication regimen for at least 4 weeks
before signing the informed consent form.

- Participants with obstructive coronary disease unsuitable for conventional
revascularization due to unsuitable anatomy or comorbidity as determined at the site
and confirmed by an independent adjudication committee.

- Participants must have evidence of inducible myocardial ischemia.

- Participants must experience angina episodes.

- Participants must be able to complete 2 exercise tolerance tests on the treadmill
within 3 weeks of randomization.

- If female of childbearing potential, subject must not be pregnant and agree to employ
adequate birth control measures for the duration of the study.

Main Exclusion Criteria:

- Cardiovascular hospitalization within 60 days prior to potential study enrollment.
Participant has had a successful or partially successful coronary artery bypass graft
(CABG) within 6 months or PCTA within 60 days of potential study enrollment.

- Participant has had a placement of a bi-ventricular pacemaker for cardiac
resynchronization therapy (CRT) for heart failure within 180 days of potential study
enrollment.

- Participant has documented stroke or transient ischemic attacks (TIAs) within 60 days
of potential study enrollment.

- Participant has a history of moderate to severe aortic stenosis; or severe aortic
insufficiency; or severe mitral stenosis; or severe mitral insufficiency.

- Participant has a prosthetic aortic valve or a mechanical mitral valve replacement.

- Participant has severe co-morbidity associated with a reduction in life expectancy to
less than 3 years as a result of chronic medical illnesses.

- Participants with cancer are excluded with the following exceptions:

- Subjects with in-situ non-melanoma skin cancer or in-situ cervical cancer are not
excluded.

- Participants that have been cancer free for >= 5 years as determined by their
oncologist are not excluded. Subjects with a prior history of stem cell
transplant for cancer are excluded no matter how long they have been cancer-free.

- Participants with a history of leukemia or other bone marrow disease.

- Participant has sickle cell disease or sickle cell trait.

- Participants with proliferative retinopathy.

- Participants with Hb A1c > 9%.

- Participant has platelet counts >10% above the upper limit of normal (ULN) or platelet
counts < 70,000.

- Participant has a hematocrit < 30% prior to potential study enrollment.

- Participant has a serum creatinine > 2.5 mg/dL prior to potential study enrollment.

- Participant tests positive for HIV, hepatitis B, or hepatitis C, or is on chronic
immunosuppressive medications, or has had a previous stem cell transplant.

- Participant has a known contraindication to Neupogen (filgrastim) or G-CSF.

- Participant was previously enrolled in an active treatment group of cell therapy
trials for cardiovascular disease including any phase of CD34+ stem cell trials.

- Left ventricular (LV) thickness of < 7 mm in the target areas of injection as measured
by during a 2-D echocardiogram (ECHO).

- Atrial fibrillation, atrial flutter, or other uncontrolled arrhythmias that would
prohibit accurate electromechanical mapping and NOGA-guided intramyocardial injection.

- Bleeding diathesis with an INR > 1.8 when not receiving anti-thrombotic therapy.

- Hepatic dysfunction as evidenced by elevated AST or ALT levels > 2.5 x ULN.

- Any previous transplant requiring immunosuppression.

- Disease state requiring chronic immunosuppression.
We found this trial at
41
sites
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Augusta, GA
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Charlotte, North Carolina 28207
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
?
mi
from
Germantown, TN
Click here to add this to my saved trials
?
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Haddon Heights, New Jersey 08035
?
mi
from
Haddon Heights, NJ
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Madison, WI
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Newark, NJ
Click here to add this to my saved trials
?
mi
from
Orlando, FL
Click here to add this to my saved trials
?
mi
from
Oxnard, CA
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Rochester, MN
Click here to add this to my saved trials
?
mi
from
Saginaw, MI
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
San Diego, CA
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Stanford, CA
Click here to add this to my saved trials
?
mi
from
Tampa, FL
Click here to add this to my saved trials